What is ARWR's P/E ratio?

ARROWHEAD PHARMACEUTICALS INC (ARWR) currently trades at a P/E ratio of 222.04.

ARROWHEAD PHARMACEUTICALS INC reports a Return on Equity (ROE) of -49.01%.

What is ARWR's dividend yield?

ARROWHEAD PHARMACEUTICALS INC offers a dividend yield of 0.00%.

What is ARWR's Deepscope Quality Score?

Deepscope rates ARWR's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy ARWR?

Deepscope's AI Timing Score for ARWR is 69 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does ARWR belong to?

ARROWHEAD PHARMACEUTICALS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.

หุ้น ARWR (NASDAQ) | ARROWHEAD PHARMACEUTICALS INC – วิเคราะห์โดย Deepscope

Stock Check ข้อมูลอัปเดตรายวัน ที่เวลา 09.30 น.
(Price: 2026-06-11 | FS: 2026-03-31)

ARWR

ARROWHEAD PHARMACEUTICALS INC

US:NASDAQ STOCK Healthcare >> Biotechnology News 99

USD 74.41

0.11 (0.15%) Day Change

Watchlist Portfolio Compare Chart

222.04

P/E

1.45

D/E

-49.0%

ROE

-13.3%

ROA

0.00%

Div Yield

8.84

PEG

ARROWHEAD PHARMACEUTICALS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 74.41 Price 0.11 (0.15%) Day Change	NEWS SCORE: 99

ARWR มีคุณภาพโดยรวมไม่ดี ( คะแนนปัจจัยพื้นฐาน = 46) และ จังหวะเข้าซื้อ ...(ล็อกอินเพื่อดู)...

Loading chart...

46 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: P/E ratio ค่อนข้างสูง
อัตราผลตอบแทนผู้ถือหุ้น (ROE) ค่อนข้างต่ำ
อัตราผลตอบแทนสินทรัพย์ (ROA) ค่อนข้างต่ำ
อัตราผลตอบแทนผู้ถือหุ้น (ROE) ในอดีต ค่อนข้างต่ำ
อัตราผลตอบแทนผู้ถือหุ้น (ROE) ลดลงอย่างมีนัยยะสำคัญ
อัตราการเติบโตของอัตราผลตอบแทนสินทรัพย์(ROA) ปัจจุบันต่ำกว่าเกณฑ์
อัตรากำไรสุทธิ ค่อนข้างต่ำ
อัตรากำไรสุทธิในอดีต ค่อนข้างต่ำ

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Lorem ipsum dolor sit amet

Unlock timing signals and detailed reasons

ถ้าดูอย่างละเอียดจะพบว่า ปัจจัยทางคุณภาพ ไม่ดี สุขภาพทางการเงิน ไม่ดี และ ประสิทธิภาพการทำกำไร ยังไม่ดีนัก , ...

ปัจจัยทางคุณภาพ

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	99
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	74.41
PBV / Sector	17.40 / 4.79
Earning Per Share	-2.15

PE / Sector	222.04 / 18.05
PEG or PE/Growth / Sector	8.84 / 0.62
Average 1M Daily Value	104.56 M GREAT
Average 1W Daily Value	95.16 M

ปัจจัยทางเทคนิค

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

สุขภาพทางการเงิน

43%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ประสิทธิภาพการทำกำไร

56%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-48.38 / 468.85
NPM Average (%) / Sector	-3,417.76 / -1,531.69
NPM Change Average (%) / Sector	11,029.66 / 5,028.65 GOOD
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-13.27 / 31.69
ROA Average (%) / Sector	-23.66 / -353.18
ROA Change Average (%) / Sector	2,792.29 / 5,214.65 GOOD
ROE (%) / Sector	-49.01 / 10.58
ROE Average (%) / Sector	-98.51 / 27.64
ROE Change Average (%) / Sector	3,550.69 / 2,048.88 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

ผลตอบแทนต่อผู้ถือหุ้น

Dividend (%) / Sector	N/A / 0.05
Dividend Average (%) / Sector	N/A / 16.49
Dividend Change Average (%) / Sector	N/A / 4.77

รายละเอียดการจดทะเบียน

Analyze Date	2026-06-12 09:43:50
Symbol	ARWR
Name	ARROWHEAD PHARMACEUTICALS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	140.86 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	10,420.60 / 9,010.81

ข่าว, ประมาณการ, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 177 East Colorado Boulevard, Pasadena, CA, United States, 91105

Phone: 626 304 3400

Website: https://arrowheadpharma.com

Employees: 711

Sector: Healthcare >> Biotechnology

Description: Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.